Clinical Trials

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03568461 2025-10-07

ELARA

98 enrolled 9 charts 2 FDA

Lymphoma, Follicular, Recurrence

NCT04466891 2025-09-15

HERIZON-BTC-01

87 enrolled 25 charts 2 FDA

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

221 enrolled 61 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03597295 2025-08-21

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

94 enrolled 18 charts 2 FDA

Squamous Cell Carcinoma of Anal Canal

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

147 enrolled 22 charts 1 FDA

Acrocephalosyndactylia, Cholangiocarcinoma

NCT03599713 2025-08-05

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

107 enrolled 16 charts 2 FDA

Dermatologic

Carcinoma, Merkel Cell

NCT02601950 2025-06-22

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

267 enrolled 25 charts 1 FDA

Sarcoma

Sarcoma, Sarcoma, Synovial

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

107 enrolled 2 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 4 FDA

Plasma cell

Multiple Myeloma

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

138 enrolled 21 charts 2 FDA

Dermatologic

Carcinoma, Basal Cell

NCT03866967 2025-02-27

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

130 enrolled 2 FDA

Head & Neck

Nasopharyngeal Carcinoma

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

117 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

86 enrolled 16 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03846427 2024-10-26

MAGNOLIA

68 enrolled 28 charts 2 FDA

Lymphoma, B-Cell, Marginal Zone

NCT02702414 2024-09-04

KEYNOTE-224

156 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03219333 2024-08-27

EV-201

219 enrolled 32 charts 3 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03284424 2024-08-23

MK-3475-629

159 enrolled 16 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02395666 2024-08-06

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

140 enrolled 14 charts 2 FDA

CNS

Neuroblastoma

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

45 enrolled 24 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02445248 2024-04-18

JULIET

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 4 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03483103 2023-12-20

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

74 enrolled 43 charts 2 FDA

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

151 enrolled 45 charts 2 FDA

CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

NCT02399085 2023-10-23

L-MIND

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03589469 2023-08-29

LOTIS-2

145 enrolled 24 charts 2 FDA

Diffuse Large B-Cell Lymphoma Refractory

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers